Long-Term Prognostic Value of 18F-FDG PET in Patients with Locally Advanced Rectal Cancer Previously Treated with Neoadjuvant Radiochemotherapy
- 1 August 2006
- journal article
- Published by American Roentgen Ray Society in American Journal of Roentgenology
- Vol. 187 (2) , W202-W208
- https://doi.org/10.2214/ajr.05.0902
Abstract
OBJECTIVE. The purpose of this study was to assess the prognostic value of 18F-FDG PET performed at restaging in patients with locally advanced rectal cancer who previously underwent neoadjuvant radiochemotherapy. SUBJECTS AND METHODS. Eighty-eight patients with histologically proven rectal cancer classified at clinical TNM stages II and III were enrolled. Six weeks after radiochemotherapy completion, all patients were restaged by sonography, CT, MRI, endoscopy, and 18F-FDG PET. Surgery was performed in all patients within 8-9 weeks from completion of radiochemotherapy. Median follow-up after surgery was 38 months (range, 6-66 months). RESULTS. The 5-year overall survival and disease-free survival were 83% and 73%, respectively. Cox multivariate analysis showed that only two parameters at restaging were independent prognostic predictors of both overall survival and disease-free survival: pathologic stage and, especially, after radiochemotherapy 18F-FDG PET findings. The 5-year overall survival was 91% in patients with a negative PET after radiochemotherapy versus 72% in those with a positive PET (p = 0.024) after radiochemotherapy, whereas disease-free survival was 81% and 62% (p = 0.003) for those with the negative and positive PET findings, respectively. Statistical data were further enhanced when combining the pathologic stage with the 18F-FDG PET results: 95% 5-year overall survival in the PET-negative pathologic stages 0 and I patients versus 70% in PET-positive pathologic stages II-IV patients (p = 0.001), whereas disease-free survival was 93% and 65% (p = 0.0003) for the negative and positive PETs, respectively. CONCLUSION. In patients with locally advanced rectal cancer previously treated with neoadjuvant radiochemotherapy, the combined evaluation of pathologic stage and after-radiochemotherapy 18F-FDG PET at restaging identified a subgroup of patients characterized by good response to radiochemotherapy and a more favorable prognosis. In these patients, a conservative surgical approach might be considered.Keywords
This publication has 36 references indexed in Scilit:
- The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancerInternational Journal of Radiation Oncology*Biology*Physics, 2005
- Fusion Image of Positron Emission Tomography and Computed Tomography for the Diagnosis of Local Recurrence of Rectal CancerAnnals of Surgical Oncology, 2005
- Restaging after neoadjuvant chemoradiotherapy for rectal adenocarcinoma: role of F18-FDG PETBiomedicine & Pharmacotherapy, 2004
- Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation: a means for determining longterm outcomes of rectal cancer1Journal of the American College of Surgeons, 2004
- Preoperative Chemoradiation for Extraperitoneal T3 Rectal Cancer: Acute Toxicity, Tumor Response, and Sphincter PreservationInternational Journal of Radiation Oncology*Biology*Physics, 1998
- Improved Survival with Preoperative Radiotherapy in Resectable Rectal CancerNew England Journal of Medicine, 1997
- Preoperative 5-FU, low-dose leucovorin, and radiation therapy for locally advanced and unresectable rectal cancerInternational Journal of Radiation Oncology*Biology*Physics, 1997
- Downstaging of advanced rectal cancer following combined preoperative chemotherapy and high dose radiationInternational Journal of Radiation Oncology*Biology*Physics, 1994
- Sampling Behavior of Tests for Correlation in Two-Way Contingency TablesJournal of the American Statistical Association, 1977
- Some Methods for Strengthening the Common χ 2 TestsPublished by JSTOR ,1954